Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Opioid Dependence

In brief

The purpose of this study is to examine the effect of memantine and buprenorphine on opioid abusing behavior, to determine the effect of memantine and buprenorphine on early relapse and to evaluate the tolerability of memantine co-administrated with buprenorphine. The study seeks to determine if combined treatment of memantine and buprenorphine may provide shorter-term treatment for opioid dependence.

Key facts

Study ID

NCT01052662

Run by

University of Massachusetts, Worcester

People needed

87

Starts

2009-10-01

Expected to finish

2013-10-01

Last updated by the study team

2015-04-01

Who can join

Age: 18 and older, up to 25. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men and women between 18-25 years old
• Opioid dependence as evidenced by signs of opiate withdrawal, self-reported history of opioid dependence for a consecutive 12 month period and positive urine for opioids

You may not qualify if…

• Current diagnosis of other drug or alcohol dependence (other than opiates, cannabis or tobacco)
• Serious medical illness (e.g. major cardiovascular, renal, endocrine, hepatic disorder)
• Current serious psychiatric illness or history of psychosis, schizophrenia, bipolar type I disorder and participants with suicidal or homicidal thoughts
• Women who are pregnant, nursing or refuse to use a reliable form of birth control or refuse monthly pregnancy testing
• Screening liver function tests (SGOT or SGPT) greater than 3 times normal

Where it is running

• University of Massachusetts Medical School — Worcester, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.